Financials data is unavailable for this security.
View more
Year on year Takeda Pharmaceutical Co Ltd had net income fall -54.56% from 317.02bn to 144.07bn despite a 5.87% increase in revenues from 4.03tn to 4.26tn. An increase in the cost of goods sold as a percentage of sales from 30.89% to 33.46% was a component in the falling net income despite rising revenues.
| Gross margin | 66.05% |
|---|---|
| Net profit margin | 6.38% |
| Operating margin | 9.80% |
| Return on assets | 1.97% |
|---|---|
| Return on equity | 4.15% |
| Return on investment | 2.35% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Takeda Pharmaceutical Co Ltd fell by 75.73bn. However, the company earned 716.34bn from its operations for a Cash Flow Margin of 16.80%. In addition the company used 463.86bn on investing activities and also paid 354.42bn in financing cash flows.
| Cash flow per share | 660.33 |
|---|---|
| Price/Cash flow per share | 6.34 |
| Book value per share | 4,365.91 |
|---|---|
| Tangible book value per share | -1,267.98 |
More ▼
Balance sheet in JPYView more
| Current ratio | 1.28 |
|---|---|
| Quick ratio | 0.7739 |
| Total debt/total equity | 0.7299 |
|---|---|
| Total debt/total capital | 0.4219 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share increased 4.44% while earnings per share excluding extraordinary items fell by -54.40%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.
| Div yield(5 year avg) | 4.70% |
|---|---|
| Div growth rate (5 year) | 0.87% |
| Payout ratio (TTM) | 104.81% |
| EPS growth(5 years) | -8.01 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 49.16 |
More ▼
